Skip to content

Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses

Alternate Dosing Strategies for Beta-hydroxy-beta-methylbutyrate (HMB) Supplementation: Effect on Plasma HMB Responses

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01914952
Enrollment
11
Registered
2013-08-02
Start date
2013-05-31
Completion date
2014-05-31
Last updated
2014-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focus of the Study is to Examine Plasma HMB Levels After Oral HMB Supplementation

Keywords

CaHMB, HMB free acid, HMB

Brief summary

The purpose of this study is to examine the rise in plasma Beta-hydroxy-beta-methylbutyrate (HMB) after the dietary supplement has been administered in different forms. Prior studies have indicated that form of administration affects bioavailability of the HMB supplement. Therefore the current study will examine the bioavailability of a single dose of HMB given as: * 1.0g CaHMB in gelatin capsule * 0.8 g HMB free acid in a gelcap * 0.8 g HMB free acid in water * 1.0 g CaHMB in water * 0.8 g HMB free acid The randomized study will be a crossover design and each study subject will undergo the experimental protocol for each of the supplementation forms. Because of the different administration forms, the study will be an open label study. Briefly, the fasted participants will report to the laboratory in the morning. After an initial blood sample is taken, the dose of HMB will be administered. Blood will then be samples at 2, 5, 10, 15, 25, 35, 45, 60, 90, 120, 180, 360, 720, and 1440 min post administration. A 24 h complete urine collection will also be performed. Participants will be given a light sack lunch 4 h after administration of the dosage and will remain at the laboratory through the 360 min sampling. Participants will then be allowed to leave the laboratory and return for the 720 min sampling after which the participants can eat an normal evening meal. Participants will return to the laboratory fasted the next morning for the final sample. A minimum 48 h washout period will be required before the next dosage form is administered and the process repeated.

Interventions

DIETARY_SUPPLEMENTCaHMB capsule

1.0 gram of CaHMB powder in a gelatin capsule

DIETARY_SUPPLEMENTHMB free acid gelcap

0.8 g HMB free acid is a soft gel capsule

DIETARY_SUPPLEMENTHMB free acid mixed in water

0.8 g HMB free acid in water

DIETARY_SUPPLEMENTCaHMB in water

1.0 g CaHMB powder mixed in water

DIETARY_SUPPLEMENTHMB free acid

0.8 g HMB free acid

Sponsors

Metabolic Technologies Inc.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 30 Years
Healthy volunteers
Yes

Inclusion criteria

* Must not be taking amino acid, protein, or HMB supplements; Must not be pregnant; Must not be breastfeeding

Exclusion criteria

* Currently taking amino acid, protein, or HMB supplements; Currently pregnant; Currently breastfeeding

Design outcomes

Primary

MeasureTime frame
Plasma HMB LevelPlasma samples collected at 0, 2, 5, 10, 15, 25, 35, 45, 60, 90, 120, 180, 360, 720, and 1440 min after treatment administration

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026